AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer

AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) continue their quest to gain additional approvals for their blockbuster cancer drug Lynparza. The duo submitted a new application to the Food and Drug Administration for the drug as a treatment for prostate cancer that's resistant to androgen depletion therapy and has metastasized to other areas of the body.

The FDA gave the application a priority review, which cuts four months off the review cycle. The pharmaceutical companies expect to hear back from the agency in the second quarter of this year although a decision could come earlier.

Doctor talking to a patient at a table

Image source: Getty Images.

Lynparza inhibits poly (ADP-ribose) polymerase (PARP) proteins that are responsible for repairing nicks in DNA. Inhibition of PARP proteins results in DNA breaks that would normally be repaired through homologous recombination, so AstraZeneca and Merck tested the drug specifically in patients with mutations in genes responsible for homologous recombination repair.

The application is based on the results of the PROfound clinical trial that tested two groups of prostate cancer patients. In patients with mutations in BRCA1/2 or ATM, Lynparza reduced the risk of disease progression by 66% compared to patients taking either Johnson & Johnson's (NYSE: JNJ) Zytiga or Astellas Pharma and Pfizer's (NYSE: PFE) Xtandi. Lynparza also extended the time it took the disease to progress while the patient remained alive from a median of 3.6 months for Zytiga or Xtanti to 7.4 months for Lynparza.

In the overall population that included patients with mutations in other homologous recombination genes, Lynparza reduced the risk of progression by 51% and extended median progression-free survival to 5.8 months, compared to 3.5 months for patients receiving Zytiga or Xtanti.

Lynparza is approved for ovarian, breast and pancreatic cancer. AstraZeneca booked Lynparza sales of $847 million in the first nine months of 2019.

10 stocks we like better than Merck & Co.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of December 1, 2019


Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More